Maa: Singapore
Kieli: englanti
Lähde: HSA (Health Sciences Authority)
Eplerenone
NOVEM PHARMA PRIVATE LIMITED
C03DA04
TABLET, FILM COATED
Eplerenone 50.000 mg
ORAL
Prescription Only
Pharmathen S.A.
ACTIVE
2024-02-06
1 1. NAME OF THE MEDICINAL PRODUCT Eplerenone MEVON 25 mg film-coated tablets Eplerenone MEVON 50 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg of eplerenone. Each tablet contains 50 mg of eplerenone. Excipients with known effect: Each 25 mg tablet contains 35.7 mg of lactose monohydrate and 0.018 mmol (0.41 mg) of sodium (see section 4.4). Each 50 mg tablet contains 71.4 mg of lactose monohydrate and 0.035 mmol (0.81 mg) of sodium (see section 4.4). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet 25 mg tablet: yellow, round biconvex tablets, 6.1mm in diameter and 2.6mm in thickness engraved with “E25” on one side 50 mg tablet: yellow, round biconvex tablets, 8.1mm in diameter and 3.3mm in thickness engraved with “E50” on one side 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS HYPERTENSION Eplerenone is indicated for the treatment of hypertension. In these patients, eplerenone may be used alone or in combination with other antihypertensive agents. HEART FAILURE - POST-MYOCARDIAL INFARCTION (MI) Eplerenone is indicated, in addition to standard therapy, to reduce the risk of cardiovascular mortality and cardiovascular hospitalization in stable patients with left ventricular dysfunction (left ventricular ejection fraction [LVEF] ≤ 40%) and clinical evidence of heart failure after recent MI. NEW YORK HEART ASSOCIATION (NYHA) CLASS II (CHRONIC) HEART FAILURE Eplerenone is indicated, in addition to standard optimal therapy to reduce the risk of cardiovascular mortality and hospitalization in heart failure adult patients with NYHA class II (chronic) heart failure and left ventricular systolic dysfunction (LVEF ≤ 30% or LVEF ≤ 35% in addition to QRS duration of >130 msec) (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION For the individual adjustment of dose, the strengths of 25 mg and 50 mg are available. 2 The maximum dose regimen is 50 mg daily for heart failure and 100 mg daily for hypertension. _ Lue koko asiakirja